Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 17/20 | 0.53 |
| ▸ | ACACA | Q13085 | 16/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4390241 | 1.00 | ACACB (0.53) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4391583 | 0.92 | ACACB (0.54) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4391594 | 0.92 | ACACB (0.54) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4394883 | 0.92 | ACACB (0.55) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4394891 | 0.92 | ACACB (0.55) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4011993 | 0.92 | ACACB (0.56) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4396141 | 0.92 | ACACB (0.60) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4396131 | 0.92 | ACACB (0.60) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4390117 | 0.90 | ACACB (0.51) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4390105 | 0.90 | ACACB (0.51) | ACACBACACACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | claimed |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885CYP1A2 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.